Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire November 06, 2025 Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key appointments in business development and human resources Cash […]
FactSet Declares Dividend GlobeNewswire November 06, 2025 NORWALK, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved a regular quarterly cash dividend of $1.10 per share. The cash dividend will be paid on December
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 06, 2025 Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care Mind Medicine Australia clinic joins Psyence BioMed's expanding network of clinical sites as enrollment accelerates in the landmark Phase IIb study for Adjustment Disorder in palliative care GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025
Marex Group plc announces third quarter 2025 results GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Marex Group plc ('Marex' or the 'Group'; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial
Immunocore reports third quarter financial results and provides a business update GlobeNewswire November 06, 2025 Immunocore reports third quarter financial results and provides a business update KIMMTRAK(R) (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 160 mcg selected
ProQR Announces Third Quarter 2025 Operating and Financial Results GlobeNewswire November 06, 2025 Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from Cohort 1 expected by year-end, and target engagement data
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease GlobeNewswire November 06, 2025 Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for planned adaptive Phase 3 trial Company
Nokia Bell Labs and KDDI Research unite to drive innovation in 6G energy efficiency and network resiliency GlobeNewswire November 06, 2025 Press ReleaseNokia Bell Labs and KDDI Research unite to drive innovation in 6G energy efficiency and network resiliency These two industry-leading research institutions are expanding their collaboration efforts to advance 6G technologies, setting the
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy GlobeNewswire November 06, 2025 Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, Nov. 06,